The Viramune® (nevirapine) tablets/oral suspension
Co-Pay Savings Card Program
The Viramune Co-Pay Savings Card Program offers qualified patients savings of up to $50 toward their monthly co-pay for up to 12 months on each VIRAMUNE prescription. Simply accept VIRAMUNE Co-Pay Savings cards from your Boehringer Ingelheim representative and distribute them to patients along with their prescription for VIRAMUNE. Then, all your patients have to do is present the following to any pharmacy (including mail-order pharmacies) that accepts MasterCard®. Patients may also receive savings on their new and pre-existing VIRAMUNE prescriptions, and their refills.
The VIRAMUNE Co-Pay Savings Card Program can help your patients save up to $50 per month
Here's how it works:
- The program provides patients with a reduction of up to $50 off the co-pay of each monthly prescription of VIRAMUNE for up to 12 months
- Simply distribute the co-pay cards to patients when they are given a prescription for VIRAMUNE
- Once the co-pay cards are activated, patients just present them, plus the required Pharmacist Information and a prescription for VIRAMUNE, to any pharmacy that accepts MasterCard®—no additional paperwork is required
- Patients can also enroll in the free Vlife on Therapy™ health and support program
- Each co-pay debit card comes with a help desk phone number. If you have any questions regarding the program, please call 1-877-411-8641
Terms and Conditions
This program expires on 12/31/2011. This offer is not valid for patients participating in Medicare, Medicaid, any other federal- or state-funded benefit programs, or where prohibited by law. Cash-paying customers are also not eligible for this offer. Offer good in the United States (including the District of Columbia and Puerto Rico) only.
Boehringer Ingelheim reserves the right to change the terms and conditions of this offer at any point. The VIRAMUNE Co-Pay Savings Card is issued by KeyBank pursuant to the license by MasterCard International Incorporated.
For cardholder service, please call the Macaluso Group at 1-877-411-8641 between 9 am and 5 pm ET, Monday through Friday, except holidays. The issuers shall not be liable to the users for losses, expenses, claims, or other damages that the user may incur as a result of this card.
INDICATION AND IMPORTANT SAFETY INFORMATION
VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on one principal clinical trial that demonstrated prolonged suppression of HIV-RNA and two smaller supportive studies.
Life-threatening and fatal hepatotoxicity has occurred in patients receiving VIRAMUNE. Any patient can experience hepatic events; however, female gender and higher CD4 counts at initiation of therapy place patients at greater risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk. VIRAMUNE should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk. Hepatic events are often associated with rash. Hepatic failure has also been reported in patients without HIV taking VIRAMUNE for post-exposure prophylaxis (PEP). Use of VIRAMUNE for occupational and non-occupational PEP is contraindicated.
Life-threatening and fatal skin reactions have also occurred, including Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction.
Patients should be intensively monitored for hepatic and skin reactions for the first 18 weeks of therapy with extra vigilance during the first 6 weeks, which is the period of greatest risk. Frequent monitoring should be performed throughout therapy with VIRAMUNE.
VIRAMUNE should be discontinued and not restarted in patients who develop signs or symptoms of hepatitis, hypersensitivity, severe skin reactions or any rash accompanied by constitutional findings. In some cases, hepatic injury has progressed despite discontinuation of treatment.
Patients with either hepatic fibrosis or cirrhosis should be monitored carefully for evidence of drug induced toxicity. VIRAMUNE should not be administered to patients with moderate or severe (Child Pugh Class B or C, respectively) hepatic impairment.
Other common side effects include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.
The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days (this has been shown to reduce the frequency of rash), followed by one 200-mg tablet twice daily. Any patient experiencing rash during the 14-day lead-in period should not increase dose until the rash has resolved. The lead-in dosing regimen should not be continued beyond 28 days.
Please see full Prescribing Information, including boxed WARNING, for VIRAMUNE.
